A global digital biomarkers market is projected to be worth over USD 22 billion by 2030, growing at a CAGR of 35.74%, claims Roots Analysis

Roots Analysis has done a detailed study on “Digital Solutions for Biomarkers Market, 2021-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 270+ page report, which features 135+ figures and 140+ tables, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html

 

Key Market Insights

• Presently, over 30 players are engaged in the development of digital solutions for different types of biomarkers; these solutions can be analyzed in silico, for a variety of diseases / clinical conditions
• The pipeline features a variety of digital solutions, which are being evaluated across different stages of development, designed to identify and analyze a diverse set of biomarkers, for use across a range of indications
• In order to maintain a competitive edge, companies engaged in the development of digital solutions for biomarkers are presently focusing on the integration of advanced features into their respective product offerings
• In the short to mid-term, considering their applicability across more than 35 target indications, more solutions for physiological / vocal biomarkers are likely to be developed for patient diagnosis / monitoring
• Case Study: The gradual shift towards incorporation of digital health tools to overcome physical confines of clinical environment is evident from ~40 global events that have recently been organized for digital biomarkers
• Foreseeing a lucrative future, several public and private investors have made investments worth around USD 1 billion, across over 110 publicly reported funding instances
• The growing interest of stakeholders is also evident from the rise in partnership activity within this domain; in fact, the maximum number of collaborations related to digital solutions for biomarkers were inked in 2020
• In order to tap into the lucrative opportunity associated with these modern solutions, several big pharma players have also undertaken diverse initiatives in this field, ranging from product development to strategic investments
• The market for digital solutions for biomarkers is expected to witness growth at an annualized rate of about 32%, from 2021-2030, with revenues from product sales coming in via both B2B and B2C channels
• The projected future opportunity for companies engaged in this field is expected to be well distributed across different therapeutic areas, purposes of solutions, and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html

 

Table of Contents

 

1.         PREFACE                    

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1        Chapter Overview

3.2.       Digitization in the Healthcare Sector

3.3.       Next-Generation Healthcare Solutions

 

Chapter Overview

3.2.       Overview of Digital Biomarkers

3.2.1     Classification of Digital Biomarkers                   

3.2.2     Key Advantages and Limitations

 

3.3.       Digital Biomarker-related Product Development and Commercialization Path

3.3.1.    Product Discovery and Development

3.3.2.    Validation and Regulatory Submissions

3.3.3.    Distribution and Marketing

 

3.4.       Prevalent Trends Related to Digital Biomarkers

3.4.1.    Emerging Focus Areas

3.4.2.    Key Historical Trends

3.4.3.    Geographical Activity

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Digital Solutions for Biomarkers: Overall Market Landscape

4.2.1.    Analysis by Current Status

4.2.2.    Analysis by Content of Solution

4.2.3.    Analysis by Purpose of Solution

4.2.4.    Analysis by Type of Biomarker

4.2.5.    Analysis by Target Indication(s)

4.2.6.    Analysis by Therapeutic Area

4.2.7.    Analysis by Target Population

4.2.8.    Analysis by Prescription Requirement

 

4.3.       Digital Solutions for Biomarkers: Developer Landscape

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size

4.3.3.    Analysis by Type of Business Model Used

4.3.4     Analysis by Location of Headquarters

 

4.4.       Leading Developers: Analysis by Number of Digital Solutions for Biomarker

4.5.       Digital Solutions for Biomarkers: Information on Additional Players

 

5.         KEY INSIGHTS

5.1.       Chapter Overview

5.2.       4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size

5.3.       Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area

5.4.       Treemap Representation: Analysis by Therapeutic Area and Company Size

5.5.       World Map Representation: Analysis by Location of Headquarters

5.6.       Current and Future Market Landscape Trends Analysis

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Acculi Labs

6.2.1     Company Overview

6.2.2.    Product Portfolio

6.2.3.    Recent Developments and Future Outlook

 

6.3.       Canary Health Technologies

6.3.1.    Company Overview

6.3.2.    Product Portfolio

6.3.3.    Recent Developments and Future Outlook

 

6.4.       Empatica

6.4.1.    Company Overview

6.4.2.    Product Portfolio

6.4.3.    Recent Developments and Future Outlook

 

6.5        IXICO

6.5.1.    Company Overview

6.5.2.    Product Portfolio

6.5.3.    Recent Developments and Future Outlook         

 

6.6.       Kinsa

6.6.1.    Company Overview

6.6.2.    Product Portfolio

6.6.3.    Recent Developments and Future Outlook

 

6.7.       Progentec Diagnostics

6.7.1.    Company Overview

6.7.2.    Product Portfolio

6.7.3.    Recent Developments and Future Outlook         

 

6.8.       Vocalis Health

6.8.1.    Company Overview

6.8.2.    Product Portfolio

6.8.3     Recent Developments and Future Outlook

 

7.         PRODUCT COMPETITIVENESS ANALYSIS

7.1.       Chapter Overview

7.2.       Key Parameters and Methodology

7.3.       Product Competitiveness Analysis

7.3.1.    Product Competitiveness Analysis: Idiosyncratic Biomarkers

7.3.2.    Product Competitiveness Analysis: Physiological Biomarkers

7.3.3.    Product Competitiveness Analysis: Vocal Biomarkers

7.3.4.    Product Competitiveness Analysis: Other Biomarkers

 

8.         GLOBAL EVENTS ANALYSIS

8.1.       Chapter Overview

8.2.       Scope and Methodology

 

8.3.       Global Events Related to Digital Biomarkers

8.3.1.    Analysis by Year of Occurrence

8.3.2.    Analysis by Event Platform

8.3.3.    Analysis by Geography

8.3.4.    Analysis by Type of Event

8.3.5.    Evolutionary Trend in Key Agenda / Event Agenda

8.3.6.    Most Active Event Organizers

8.3.7.    Most Active Players in Terms of Event Participation

8.3.8.    Analysis by Seniority Level of Participants

 

9.         FUNDING AND INVESTMENT ANALYSIS

9.1.       Chapter Overview

9.2.       Types of Funding

 

9.3.       Digital Solutions for Biomarkers: Funding and Investment Analysis

9.3.1.    Analysis by Number of Funding Instances

9.3.2.    Analysis by Amount Invested

9.3.3.    Analysis by Type of Funding

9.3.4.    Analysis by Type of Biomarker

9.3.5.    Analysis by Therapeutic Area

9.3.6.    Analysis by Geography

9.3.7.    Most Active Players: Analysis by Number of Instances

9.3.8.    Most Active Players: Analysis by Amount Invested

9.3.9.    Most Active Investors: Analysis by Number of Instances

                       

9.4        Concluding Remarks

 

10.        PARTNERSHIPS AND COLLABORATIONS